STOCK TITAN

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BioCardia (NASDAQ:BCDA), a company specializing in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has scheduled its Q1 2025 corporate update and financial results conference call for May 14, 2025, at 4:30 PM EDT. The call will include management's formal remarks followed by a Q&A session.

Participants can pre-register online or join by phone: U.S. callers should dial 1-833-316-0559, while international callers should use 1-412-317-5730. A live webcast will be available, and replay options will be accessible until May 28, 2025, through both web and telephone platforms.

BioCardia (NASDAQ:BCDA), azienda specializzata in terapie cellulari e derivate per malattie cardiovascolari e polmonari, ha programmato la sua conferenza per l'aggiornamento aziendale e i risultati finanziari del primo trimestre 2025 per il 14 maggio 2025 alle 16:30 EDT. La chiamata includerà gli interventi ufficiali del management seguiti da una sessione di domande e risposte.

I partecipanti possono preregistrarsi online o partecipare telefonicamente: i chiamanti dagli Stati Uniti devono chiamare il numero 1-833-316-0559, mentre quelli internazionali il 1-412-317-5730. Sarà disponibile una diretta web e le opzioni di replay saranno accessibili fino al 28 maggio 2025 sia via web che telefono.

BioCardia (NASDAQ:BCDA), una empresa especializada en terapias celulares y derivadas para enfermedades cardiovasculares y pulmonares, ha programado su llamada de actualización corporativa y resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025 a las 4:30 PM EDT. La llamada incluirá las declaraciones formales de la dirección seguidas de una sesión de preguntas y respuestas.

Los participantes pueden pre-registrarse en línea o unirse por teléfono: los llamantes en EE.UU. deben marcar 1-833-316-0559, mientras que los internacionales deben usar 1-412-317-5730. Habrá una transmisión en vivo disponible y opciones de repetición accesibles hasta el 28 de mayo de 2025 a través de plataformas web y telefónicas.

BioCardia (NASDAQ:BCDA)는 심혈관 및 폐 질환을 위한 세포 및 세포 유래 치료제 전문 기업으로, 2025년 1분기 기업 업데이트 및 재무 실적 컨퍼런스 콜을 2025년 5월 14일 오후 4시 30분 EDT에 예정하고 있습니다. 콜에는 경영진의 공식 발언과 질의응답 시간이 포함됩니다.

참가자는 온라인 사전 등록하거나 전화로 참여할 수 있습니다: 미국 내 전화는 1-833-316-0559, 해외 전화는 1-412-317-5730으로 전화하십시오. 생중계 웹캐스트가 제공되며, 재청취 옵션은 2025년 5월 28일까지 웹과 전화 플랫폼을 통해 이용 가능합니다.

BioCardia (NASDAQ:BCDA), une société spécialisée dans les thérapies cellulaires et dérivées pour les maladies cardiovasculaires et pulmonaires, a programmé sa mise à jour d'entreprise et la conférence téléphonique des résultats financiers du premier trimestre 2025 pour le 14 mai 2025 à 16h30 EDT. L'appel comprendra les remarques officielles de la direction suivies d'une session de questions-réponses.

Les participants peuvent s'inscrire à l'avance en ligne ou rejoindre par téléphone : les appelants aux États-Unis doivent composer le 1-833-316-0559, tandis que les appelants internationaux doivent utiliser le 1-412-317-5730. Un webcast en direct sera disponible, et les options de replay seront accessibles jusqu'au 28 mai 2025 via les plateformes web et téléphoniques.

BioCardia (NASDAQ:BCDA), ein Unternehmen, das sich auf zelluläre und zellbasierte Therapeutika für Herz-Kreislauf- und Lungenerkrankungen spezialisiert hat, hat seine Unternehmensaktualisierung und Finanzberichterstattung für das erste Quartal 2025 für den 14. Mai 2025 um 16:30 Uhr EDT angesetzt. Der Anruf umfasst formelle Ausführungen des Managements, gefolgt von einer Fragerunde.

Teilnehmer können sich online vorab registrieren oder telefonisch teilnehmen: US-Anrufer wählen 1-833-316-0559, internationale Anrufer 1-412-317-5730. Ein Live-Webcast wird verfügbar sein, und Wiederholungsoptionen sind bis zum 28. Mai 2025 über Web- und Telefonplattformen zugänglich.

Positive
  • None.
Negative
  • None.

SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.  

Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZrMeNX6o.

A webcast replay of the call will be available approximately one hour after the end of the call through approximately May 28, 2025 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 4465715.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.



MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120

FAQ

When is BioCardia (BCDA) reporting Q1 2025 earnings?

BioCardia (BCDA) will report its Q1 2025 financial results on Wednesday, May 14, 2025, at 4:30 PM EDT.

How can I join BioCardia's Q1 2025 earnings call?

You can join by registering online at dpregister.com, calling 1-833-316-0559 (US) or 1-412-317-5730 (international), or accessing the live webcast through the company's provided link.

What is the replay access code for BioCardia's Q1 2025 earnings call?

The replay access code is 4465715, available by calling 1-877-344-7529 (US), 1-412-317-0088 (international), or 855-669-9658 (Canada).

Until when is BioCardia's Q1 2025 earnings call replay available?

The earnings call replay will be available until May 28, 2025, through both webcast and telephonic platforms.
Biocardia Inc

NASDAQ:BCDA

BCDA Rankings

BCDA Latest News

BCDA Stock Data

10.93M
4.04M
21.73%
2.72%
0.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SUNNYVALE